Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197078 · ClinicalTrials.gov registry record
Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 189,426
- Enrollment target
NCT02197078 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 189,426 participants.
The verdict
NCT02197078 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 189,426 participants
- Enrollment target
Study Summary
This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety of health outcomes. The primary analysis will be conducted among patients without prior within-class medication use.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189,426 participants |
| Start Date | 2014-07-30 |
| Est. Completion | 2019-02-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02197078
The ClinicalTrials.gov registry entry for NCT02197078 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 189,426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02197078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02197078 about?
NCT02197078 is a clinical study titled "Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin". This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety of health outcomes. The prim...
What is the current status of trial NCT02197078?
This trial is currently completed. The enrollment target is 189,426 participants. The study started on 2014-07-30. Estimated completion is 2019-02-26.
Who is sponsoring clinical trial NCT02197078?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.